{"id":"W4389623269","doi":"10.1016/j.clml.2023.12.005","title":"Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital; Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche; Roche; Roche Canada","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Follicular lymphoma; Neutropenia; Lymphoma; Adverse effect; Febrile neutropenia; Gastroenterology; Tumor lysis syndrome; Refractory (planetary science); Rituximab; Cyclophosphamide; Oncology; Surgery; Cancer; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002811359,0.000838618,0.002118572,0.0004963415,0.0003397979,0.00009451952,0.0009986726,0.0009748288,0.002096807],"category_scores_gemma":[0.000853455,0.0007138659,0.0008403664,0.001819541,0.001062709,0.0003523956,0.001010901,0.0009432687,0.001290082],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002541401,"about_ca_system_score_gemma":0.002122701,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002914053,"about_ca_topic_score_gemma":0.00003764196,"domain_scores_codex":[0.9893112,0.0008861443,0.003711313,0.002390237,0.002097063,0.001604059],"domain_scores_gemma":[0.9934031,0.002179987,0.0006885421,0.002294325,0.0002948527,0.001139182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2504818,0.01145148,0.05636534,0.00007815563,0.0003407872,0.001621627,0.0005220108,0.000005027529,0.0001541929,0.00001377813,0.005902842,0.6730629],"study_design_scores_gemma":[0.3404185,0.01581188,0.6163347,0.0002780947,0.0001396905,0.000006034832,0.0002901874,0.001205095,0.0001662298,0.00003600526,0.02472477,0.0005888374],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844885,0.00008218259,0.00003901993,0.0001688257,0.00183294,0.004566619,0.0001525104,0.0003925183,0.00827685],"genre_scores_gemma":[0.9824604,0.0004567742,0.001212586,0.0006680589,0.001417899,0.0006541195,0.001049228,0.0002334839,0.0118474],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6724741,"threshold_uncertainty_score":0.9995313,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03510957312794868,"score_gpt":0.3631146871045697,"score_spread":0.328005113976621,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}